Share on LinkedInShare on LinkedIn

ARTICLE · 13 APRIL 2017

March 2017 Deal Round-Up

Cassels
Cassels
Contributor
Cassels

Cassels

Cassels Brock & Blackwell LLP is a Canadian law firm focused on serving the transaction, advocacy,...

View firm profile
Explore more from Cassels

The following is a selection of major deals in the life science space that closed or were announced as closed in March 2017.

CanadaCorporate/Commercial Law

The following is a selection of major deals in the life science space that closed or were announced as closed in March 2017.

MERGERS & ACQUISITIONS
Date: March 3, 2017

Type: Acquisition

Target: Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX; TSX:VRX) (specifically, Valeant's CeraVe, AcneFree and AMBI skincare brands)

Acquirer: L'Oréal SA ("L'Oréal")

Deal size: US $1.3 billion

Description: On March 3, 2017, Valeant announced the completion of the sale of its CeraVe, AcneFree and AMBI skincare brands to L'Oréal SA for cash consideration of $1.3 billion. Valeant indicated that the rationale for the sale was to generate cash to pay down debt while L'Oréal indicated that it purchased these brands in order to, among other things, complement L'Oréal's current brand portfolio.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from